A statistical method was developed to measure longitudinal changes in CA125 levels, and screening trials have recently been performed in which the risk of ovarian cancer algorithm has been used in combination with transvaginal ultrasound [10–12]. This evidence concerns the gene MUC16 and ovarian carcinoma.